Browse by UCL Departments and Centres
![[up]](/style/images/multi_up.png)
Up a levelGroup by: Author | Type
Number of items: 13.
E
Emary, KRW;
Golubchik, T;
Aley, PK;
Ariani, CV;
Angus, B;
Bibi, S;
Blane, B;
... Oxford COVID-19 Vaccine Trial Group; + view all
(2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
The Lancet
, 397
(10282)
pp. 1351-1362.
10.1016/S0140-6736(21)00628-0.
|
 |
F
|
Feng, S;
Phillips, DJ;
White, T;
Sayal, H;
Aley, PK;
Bibi, S;
Dold, C;
... Williams, CJ; + view all
(2021)
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Nature Medicine
10.1038/s41591-021-01540-1.
|
|
|
Flaxman, Amy;
Marchevsky, Natalie G;
Jenkin, Daniel;
Aboagye, Jeremy;
Aley, Parvinder K;
Angus, Brian;
Belij-Rammerstorfer, Sandra;
... Lambe, Teresa; + view all
(2021)
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
, 398
(10304)
pp. 981-990.
10.1016/S0140-6736(21)01699-8.
|
|
I
|
Islam, A;
Simeoni, S;
Panicker, J;
Batla, A;
(2021)
Exploratory pilot study exploring clinical effects of exogenous sustained-release Melatonin on nocturia in Parkinson’s Disease.
European Journal of Neurology
, 28
(6)
pp. 1884-1892.
10.1111/ene.14774.
|
|
L
|
Lazarus, R;
Baos, S;
Cappel-Porter, H;
Carson-Stevens, A;
Clout, M;
Culliford, L;
Emmett, SR;
... ComfluCOV Trial Group; + view all
(2021)
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
The Lancet
10.1016/S0140-6736(21)02329-1.
(In press).
|
|
|
Liu, X;
Shaw, RH;
Stuart, ASV;
Greenland, M;
Aley, PK;
Andrews, NJ;
Cameron, JC;
... Allen, L; + view all
(2021)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
The Lancet
, 398
(10303)
pp. 856-869.
10.1016/S0140-6736(21)01694-9.
|
|
M
|
McLaughlin, Jonathan;
Young, Tim;
(2021)
Neurology in the psychiatric patient: how to think about differentials in altered mental status and diagnoses not to miss.
BJPsych Advances
, 28
(4)
pp. 226-238.
10.1192/bja.2021.67.
|
|
Munro, APS;
Janani, L;
Cornelius, V;
Aley, PK;
Babbage, G;
Baxter, D;
Bula, M;
... COV-BOOST study group; + view all
(2021)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet
, 398
(10318)
pp. 2258-2276.
10.1016/S0140-6736(21)02717-3.
|
|
S
|
Stuart, ASV;
Shaw, RH;
Liu, X;
Greenland, M;
Aley, PK;
Andrews, NJ;
Cameron, JC;
... Com-COV2 Study Group; + view all
(2021)
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
10.1016/S0140-6736(21)02718-5.
(In press).
|
|
V
|
Vijiaratnam, N;
Girges, C;
Auld, G;
Chau, M;
Maclagan, K;
King, A;
Skene, S;
... Foltynie, T; + view all
(2021)
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
BMJ Open
, 11
(5)
, Article e047993. 10.1136/bmjopen-2020-047993.
|
|
|
Voysey, M;
Costa Clemens, SA;
Madhi, SA;
Weckx, LY;
Folegatti, PM;
Aley, PK;
Angus, B;
... Oxford COVID Vaccine Trial Group, .; + view all
(2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
The Lancet
, 397
(10277)
pp. 881-891.
10.1016/S0140-6736(21)00432-3.
|
|
W
|
Wall, EC;
Wu, M;
Harvey, R;
Kelly, G;
Warchal, S;
Sawyer, C;
Daniels, R;
... Bauer, DL; + view all
(2021)
AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.
The Lancet
10.1016/S0140-6736(21)01462-8.
(In press).
|
|
|
Wall, EC;
Wu, M;
Harvey, R;
Kelly, G;
Warchal, S;
Sawyer, C;
Daniels, R;
... Bauer, DLV; + view all
(2021)
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
The Lancet
10.1016/s0140-6736(21)01290-3.
(In press).
|
|
